img

Global Anti-tuberculosis Therapeutics Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global Anti-tuberculosis Therapeutics Market Insights, Forecast to 2034

Tuberculosis (TB) is a disease affecting the population across the world. Although tuberculosis is a curable disease, it still remains one of the most common causes of death among adults, particularly in the emerging economies.
Market Analysis and InsightsGlobal Anti-tuberculosis Therapeutics Market
Global Anti-tuberculosis Therapeutics market is expected to reach to US$ million in 2023, with a positive growth of %, compared with US$ million in 2022. Backed with the increasing demand from downstream industries, Anti-tuberculosis Therapeutics industry is evaluated to reach US$ million in 2033. The CAGR will be % during 2023 to 2033.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global Anti-tuberculosis Therapeutics market from 2018 to 2033, aiming to help readers to get a comprehensive understanding of global Anti-tuberculosis Therapeutics market with multiple angles. Items like regional revenue from 2018 to 2033 and companies’ revenue and gross margin from 2018 to 2023 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2033 are also highlighted.
Companies, Type, Application and Regions Listed in the Report



By Company


Lupin
Macleods Pharmaceuticals
Otsuka Pharmaceutical
Johnson & Johnson
Pfizer
Novartis
Abbott
AstraZeneca
Bayer
Eli Lilly
GlaxoSmithKline
Merck
Sanofi
Segment by Type
Isoniazid
Rifampin
Ethambutol
Pyrazinamide
Otherr

Segment by Application


Hospitals and Clinics
Government Agencies
Non-Profit Organizations
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2033
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2033 globally
Chapter 5Product revenue analysis by application from 2018 to 2033 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2033 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2033
Chapter 7Product revenue analysis by type and application from 2018 to 2033 in Europe. Product revenue analysis of each country in Europe from 2018 to 2033
Chapter 8Product revenue analysis by type and application from 2018 to 2033 in China. Product revenue analysis of China from 2018 to 2033
Chapter 9Product revenue analysis by type and application from 2018 to 2033 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2033
Chapter 10Product revenue analysis by type and application from 2018 to 2033 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2033.
Chapter 11Companies’ outline, covering company’s basic information, major business, Anti-tuberculosis Therapeutics introduction, etc. Anti-tuberculosis Therapeutics Revenue and Gross Margin of each company from 2018 to 2023
Chapter 12MRAResearch’s Conclusions of Anti-tuberculosis Therapeutics
Chapter 13Methodology and Data Sources adopted by MRAResearch

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Anti-tuberculosis Therapeutics Market Size Growth Rate by Type, 2018 VS 2022 VS 2033
1.2.2 Isoniazid
1.2.3 Rifampin
1.2.4 Ethambutol
1.2.5 Pyrazinamide
1.2.6 Otherr
1.3 Market by Application
1.3.1 Global Anti-tuberculosis Therapeutics Market Size Growth Rate by Application, 2018 VS 2022 VS 2033
1.3.2 Hospitals and Clinics
1.3.3 Government Agencies
1.3.4 Non-Profit Organizations
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Anti-tuberculosis Therapeutics Market Perspective (2018-2033)
2.2 Global Anti-tuberculosis Therapeutics Growth Trends by Region
2.2.1 Anti-tuberculosis Therapeutics Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Anti-tuberculosis Therapeutics Historic Market Size by Region (2018-2023)
2.2.3 Anti-tuberculosis Therapeutics Forecasted Market Size by Region (2024-2033)
2.3 Anti-tuberculosis Therapeutics Market Dynamics
2.3.1 Anti-tuberculosis Therapeutics Industry Trends
2.3.2 Anti-tuberculosis Therapeutics Market Drivers
2.3.3 Anti-tuberculosis Therapeutics Market Challenges
2.3.4 Anti-tuberculosis Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Anti-tuberculosis Therapeutics by Players
3.1.1 Global Anti-tuberculosis Therapeutics Revenue by Players (2018-2023)
3.1.2 Global Anti-tuberculosis Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global Anti-tuberculosis Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Anti-tuberculosis Therapeutics, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Anti-tuberculosis Therapeutics Market Concentration Ratio
3.4.1 Global Anti-tuberculosis Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Anti-tuberculosis Therapeutics Revenue in 2022
3.5 Global Key Players of Anti-tuberculosis Therapeutics Head office and Area Served
3.6 Global Key Players of Anti-tuberculosis Therapeutics, Product and Application
3.7 Global Key Players of Anti-tuberculosis Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Anti-tuberculosis Therapeutics Breakdown Data by Type
4.1 Global Anti-tuberculosis Therapeutics Historic Market Size by Type (2018-2023)
4.2 Global Anti-tuberculosis Therapeutics Forecasted Market Size by Type (2024-2033)
5 Anti-tuberculosis Therapeutics Breakdown Data by Application
5.1 Global Anti-tuberculosis Therapeutics Historic Market Size by Application (2018-2023)
5.2 Global Anti-tuberculosis Therapeutics Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Anti-tuberculosis Therapeutics Market Size (2018-2033)
6.2 North America Anti-tuberculosis Therapeutics Market Size by Type
6.2.1 North America Anti-tuberculosis Therapeutics Market Size by Type (2018-2023)
6.2.2 North America Anti-tuberculosis Therapeutics Market Size by Type (2024-2033)
6.2.3 North America Anti-tuberculosis Therapeutics Market Share by Type (2018-2033)
6.3 North America Anti-tuberculosis Therapeutics Market Size by Application
6.3.1 North America Anti-tuberculosis Therapeutics Market Size by Application (2018-2023)
6.3.2 North America Anti-tuberculosis Therapeutics Market Size by Application (2024-2033)
6.3.3 North America Anti-tuberculosis Therapeutics Market Share by Application (2018-2033)
6.4 North America Anti-tuberculosis Therapeutics Market Size by Country
6.4.1 North America Anti-tuberculosis Therapeutics Market Size by Country: 2018 VS 2022 VS 2033
6.4.2 North America Anti-tuberculosis Therapeutics Market Size by Country (2018-2023)
6.4.3 North America Anti-tuberculosis Therapeutics Market Size by Country (2024-2033)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Anti-tuberculosis Therapeutics Market Size (2018-2033)
7.2 Europe Anti-tuberculosis Therapeutics Market Size by Type
7.2.1 Europe Anti-tuberculosis Therapeutics Market Size by Type (2018-2023)
7.2.2 Europe Anti-tuberculosis Therapeutics Market Size by Type (2024-2033)
7.2.3 Europe Anti-tuberculosis Therapeutics Market Share by Type (2018-2033)
7.3 Europe Anti-tuberculosis Therapeutics Market Size by Application
7.3.1 Europe Anti-tuberculosis Therapeutics Market Size by Application (2018-2023)
7.3.2 Europe Anti-tuberculosis Therapeutics Market Size by Application (2024-2033)
7.3.3 Europe Anti-tuberculosis Therapeutics Market Share by Application (2018-2033)
7.4 Europe Anti-tuberculosis Therapeutics Market Size by Country
7.4.1 Europe Anti-tuberculosis Therapeutics Market Size by Country: 2018 VS 2022 VS 2033
7.4.2 Europe Anti-tuberculosis Therapeutics Market Size by Country (2018-2023)
7.4.3 Europe Anti-tuberculosis Therapeutics Market Size by Country (2024-2033)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Anti-tuberculosis Therapeutics Market Size (2018-2033)
8.2 China Anti-tuberculosis Therapeutics Market Size by Type
8.2.1 China Anti-tuberculosis Therapeutics Market Size by Type (2018-2023)
8.2.2 China Anti-tuberculosis Therapeutics Market Size by Type (2024-2033)
8.2.3 China Anti-tuberculosis Therapeutics Market Share by Type (2018-2033)
8.3 China Anti-tuberculosis Therapeutics Market Size by Application
8.3.1 China Anti-tuberculosis Therapeutics Market Size by Application (2018-2023)
8.3.2 China Anti-tuberculosis Therapeutics Market Size by Application (2024-2033)
8.3.3 China Anti-tuberculosis Therapeutics Market Share by Application (2018-2033)
9 Asia (excluding China)
9.1 Asia Anti-tuberculosis Therapeutics Market Size (2018-2033)
9.2 Asia Anti-tuberculosis Therapeutics Market Size by Type
9.2.1 Asia Anti-tuberculosis Therapeutics Market Size by Type (2018-2023)
9.2.2 Asia Anti-tuberculosis Therapeutics Market Size by Type (2024-2033)
9.2.3 Asia Anti-tuberculosis Therapeutics Market Share by Type (2018-2033)
9.3 Asia Anti-tuberculosis Therapeutics Market Size by Application
9.3.1 Asia Anti-tuberculosis Therapeutics Market Size by Application (2018-2023)
9.3.2 Asia Anti-tuberculosis Therapeutics Market Size by Application (2024-2033)
9.3.3 Asia Anti-tuberculosis Therapeutics Market Share by Application (2018-2033)
9.4 Asia Anti-tuberculosis Therapeutics Market Size by Region
9.4.1 Asia Anti-tuberculosis Therapeutics Market Size by Region: 2018 VS 2022 VS 2033
9.4.2 Asia Anti-tuberculosis Therapeutics Market Size by Region (2018-2023)
9.4.3 Asia Anti-tuberculosis Therapeutics Market Size by Region (2024-2033)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Anti-tuberculosis Therapeutics Market Size (2018-2033)
10.2 Middle East, Africa, and Latin America Anti-tuberculosis Therapeutics Market Size by Type
10.2.1 Middle East, Africa, and Latin America Anti-tuberculosis Therapeutics Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Anti-tuberculosis Therapeutics Market Size by Type (2024-2033)
10.2.3 Middle East, Africa, and Latin America Anti-tuberculosis Therapeutics Market Share by Type (2018-2033)
10.3 Middle East, Africa, and Latin America Anti-tuberculosis Therapeutics Market Size by Application
10.3.1 Middle East, Africa, and Latin America Anti-tuberculosis Therapeutics Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Anti-tuberculosis Therapeutics Market Size by Application (2024-2033)
10.3.3 Middle East, Africa, and Latin America Anti-tuberculosis Therapeutics Market Share by Application (2018-2033)
10.4 Middle East, Africa, and Latin America Anti-tuberculosis Therapeutics Market Size by Country
10.4.1 Middle East, Africa, and Latin America Anti-tuberculosis Therapeutics Market Size by Country: 2018 VS 2022 VS 2033
10.4.2 Middle East, Africa, and Latin America Anti-tuberculosis Therapeutics Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Anti-tuberculosis Therapeutics Market Size by Country (2024-2033)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Lupin
11.1.1 Lupin Company Details
11.1.2 Lupin Business Overview
11.1.3 Lupin Anti-tuberculosis Therapeutics Introduction
11.1.4 Lupin Revenue in Anti-tuberculosis Therapeutics Business (2018-2023)
11.1.5 Lupin Recent Developments
11.2 Macleods Pharmaceuticals
11.2.1 Macleods Pharmaceuticals Company Details
11.2.2 Macleods Pharmaceuticals Business Overview
11.2.3 Macleods Pharmaceuticals Anti-tuberculosis Therapeutics Introduction
11.2.4 Macleods Pharmaceuticals Revenue in Anti-tuberculosis Therapeutics Business (2018-2023)
11.2.5 Macleods Pharmaceuticals Recent Developments
11.3 Otsuka Pharmaceutical
11.3.1 Otsuka Pharmaceutical Company Details
11.3.2 Otsuka Pharmaceutical Business Overview
11.3.3 Otsuka Pharmaceutical Anti-tuberculosis Therapeutics Introduction
11.3.4 Otsuka Pharmaceutical Revenue in Anti-tuberculosis Therapeutics Business (2018-2023)
11.3.5 Otsuka Pharmaceutical Recent Developments
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Details
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson Anti-tuberculosis Therapeutics Introduction
11.4.4 Johnson & Johnson Revenue in Anti-tuberculosis Therapeutics Business (2018-2023)
11.4.5 Johnson & Johnson Recent Developments
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Anti-tuberculosis Therapeutics Introduction
11.5.4 Pfizer Revenue in Anti-tuberculosis Therapeutics Business (2018-2023)
11.5.5 Pfizer Recent Developments
11.6 Novartis
11.6.1 Novartis Company Details
11.6.2 Novartis Business Overview
11.6.3 Novartis Anti-tuberculosis Therapeutics Introduction
11.6.4 Novartis Revenue in Anti-tuberculosis Therapeutics Business (2018-2023)
11.6.5 Novartis Recent Developments
11.7 Abbott
11.7.1 Abbott Company Details
11.7.2 Abbott Business Overview
11.7.3 Abbott Anti-tuberculosis Therapeutics Introduction
11.7.4 Abbott Revenue in Anti-tuberculosis Therapeutics Business (2018-2023)
11.7.5 Abbott Recent Developments
11.8 AstraZeneca
11.8.1 AstraZeneca Company Details
11.8.2 AstraZeneca Business Overview
11.8.3 AstraZeneca Anti-tuberculosis Therapeutics Introduction
11.8.4 AstraZeneca Revenue in Anti-tuberculosis Therapeutics Business (2018-2023)
11.8.5 AstraZeneca Recent Developments
11.9 Bayer
11.9.1 Bayer Company Details
11.9.2 Bayer Business Overview
11.9.3 Bayer Anti-tuberculosis Therapeutics Introduction
11.9.4 Bayer Revenue in Anti-tuberculosis Therapeutics Business (2018-2023)
11.9.5 Bayer Recent Developments
11.10 Eli Lilly
11.10.1 Eli Lilly Company Details
11.10.2 Eli Lilly Business Overview
11.10.3 Eli Lilly Anti-tuberculosis Therapeutics Introduction
11.10.4 Eli Lilly Revenue in Anti-tuberculosis Therapeutics Business (2018-2023)
11.10.5 Eli Lilly Recent Developments
11.11 GlaxoSmithKline
11.11.1 GlaxoSmithKline Company Details
11.11.2 GlaxoSmithKline Business Overview
11.11.3 GlaxoSmithKline Anti-tuberculosis Therapeutics Introduction
11.11.4 GlaxoSmithKline Revenue in Anti-tuberculosis Therapeutics Business (2018-2023)
11.11.5 GlaxoSmithKline Recent Developments
11.12 Merck
11.12.1 Merck Company Details
11.12.2 Merck Business Overview
11.12.3 Merck Anti-tuberculosis Therapeutics Introduction
11.12.4 Merck Revenue in Anti-tuberculosis Therapeutics Business (2018-2023)
11.12.5 Merck Recent Developments
11.13 Sanofi
11.13.1 Sanofi Company Details
11.13.2 Sanofi Business Overview
11.13.3 Sanofi Anti-tuberculosis Therapeutics Introduction
11.13.4 Sanofi Revenue in Anti-tuberculosis Therapeutics Business (2018-2023)
11.13.5 Sanofi Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Anti-tuberculosis Therapeutics Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2033
Table 2. Key Players of Isoniazid
Table 3. Key Players of Rifampin
Table 4. Key Players of Ethambutol
Table 5. Key Players of Pyrazinamide
Table 6. Key Players of Otherr
Table 7. Global Anti-tuberculosis Therapeutics Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2033
Table 8. Global Anti-tuberculosis Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 9. Global Anti-tuberculosis Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 10. Global Anti-tuberculosis Therapeutics Market Share by Region (2018-2023)
Table 11. Global Anti-tuberculosis Therapeutics Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 12. Global Anti-tuberculosis Therapeutics Market Share by Region (2024-2033)
Table 13. Anti-tuberculosis Therapeutics Market Trends
Table 14. Anti-tuberculosis Therapeutics Market Drivers
Table 15. Anti-tuberculosis Therapeutics Market Challenges
Table 16. Anti-tuberculosis Therapeutics Market Restraints
Table 17. Global Anti-tuberculosis Therapeutics Revenue by Players (2018-2023) & (US$ Million)
Table 18. Global Anti-tuberculosis Therapeutics Revenue Share by Players (2018-2023)
Table 19. Global Top Anti-tuberculosis Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-tuberculosis Therapeutics as of 2022)
Table 20. Global Anti-tuberculosis Therapeutics Industry Ranking 2021 VS 2022 VS 2023
Table 21. Global 5 Largest Players Market Share by Anti-tuberculosis Therapeutics Revenue (CR5 and HHI) & (2018-2023)
Table 22. Global Key Players of Anti-tuberculosis Therapeutics, Headquarters and Area Served
Table 23. Global Key Players of Anti-tuberculosis Therapeutics, Product and Application
Table 24. Global Key Players of Anti-tuberculosis Therapeutics, Product and Application
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Anti-tuberculosis Therapeutics Market Size by Type (2018-2023) & (US$ Million)
Table 27. Global Anti-tuberculosis Therapeutics Revenue Market Share by Type (2018-2023)
Table 28. Global Anti-tuberculosis Therapeutics Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 29. Global Anti-tuberculosis Therapeutics Revenue Market Share by Type (2024-2033)
Table 30. Global Anti-tuberculosis Therapeutics Market Size by Application (2018-2023) & (US$ Million)
Table 31. Global Anti-tuberculosis Therapeutics Revenue Share by Application (2018-2023)
Table 32. Global Anti-tuberculosis Therapeutics Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 33. Global Anti-tuberculosis Therapeutics Revenue Share by Application (2024-2033)
Table 34. North America Anti-tuberculosis Therapeutics Market Size by Type (2018-2023) & (US$ Million)
Table 35. North America Anti-tuberculosis Therapeutics Market Size by Type (2024-2033) & (US$ Million)
Table 36. North America Anti-tuberculosis Therapeutics Market Size by Application (2018-2023) & (US$ Million)
Table 37. North America Anti-tuberculosis Therapeutics Market Size by Application (2024-2033) & (US$ Million)
Table 38. North America Anti-tuberculosis Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 39. North America Anti-tuberculosis Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 40. North America Anti-tuberculosis Therapeutics Market Size by Country (2024-2033) & (US$ Million)
Table 41. Europe Anti-tuberculosis Therapeutics Market Size by Type (2018-2023) & (US$ Million)
Table 42. Europe Anti-tuberculosis Therapeutics Market Size by Type (2024-2033) & (US$ Million)
Table 43. Europe Anti-tuberculosis Therapeutics Market Size by Application (2018-2023) & (US$ Million)
Table 44. Europe Anti-tuberculosis Therapeutics Market Size by Application (2024-2033) & (US$ Million)
Table 45. Europe Anti-tuberculosis Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 46. Europe Anti-tuberculosis Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 47. Europe Anti-tuberculosis Therapeutics Market Size by Country (2024-2033) & (US$ Million)
Table 48. China Anti-tuberculosis Therapeutics Market Size by Type (2018-2023) & (US$ Million)
Table 49. China Anti-tuberculosis Therapeutics Market Size by Type (2024-2033) & (US$ Million)
Table 50. China Anti-tuberculosis Therapeutics Market Size by Application (2018-2023) & (US$ Million)
Table 51. China Anti-tuberculosis Therapeutics Market Size by Application (2024-2033) & (US$ Million)
Table 52. Asia Anti-tuberculosis Therapeutics Market Size by Type (2018-2023) & (US$ Million)
Table 53. Asia Anti-tuberculosis Therapeutics Market Size by Type (2024-2033) & (US$ Million)
Table 54. Asia Anti-tuberculosis Therapeutics Market Size by Application (2018-2023) & (US$ Million)
Table 55. Asia Anti-tuberculosis Therapeutics Market Size by Application (2024-2033) & (US$ Million)
Table 56. Asia Anti-tuberculosis Therapeutics Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 57. Asia Anti-tuberculosis Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 58. Asia Anti-tuberculosis Therapeutics Market Size by Region (2024-2033) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Anti-tuberculosis Therapeutics Market Size by Type (2018-2023) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Anti-tuberculosis Therapeutics Market Size by Type (2024-2033) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Anti-tuberculosis Therapeutics Market Size by Application (2018-2023) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Anti-tuberculosis Therapeutics Market Size by Application (2024-2033) & (US$ Million)
Table 63. Middle East, Africa, and Latin America Anti-tuberculosis Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 64. Middle East, Africa, and Latin America Anti-tuberculosis Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 65. Middle East, Africa, and Latin America Anti-tuberculosis Therapeutics Market Size by Country (2024-2033) & (US$ Million)
Table 66. Lupin Company Details
Table 67. Lupin Business Overview
Table 68. Lupin Anti-tuberculosis Therapeutics Product
Table 69. Lupin Revenue in Anti-tuberculosis Therapeutics Business (2018-2023) & (US$ Million)
Table 70. Lupin Recent Developments
Table 71. Macleods Pharmaceuticals Company Details
Table 72. Macleods Pharmaceuticals Business Overview
Table 73. Macleods Pharmaceuticals Anti-tuberculosis Therapeutics Product
Table 74. Macleods Pharmaceuticals Revenue in Anti-tuberculosis Therapeutics Business (2018-2023) & (US$ Million)
Table 75. Macleods Pharmaceuticals Recent Developments
Table 76. Otsuka Pharmaceutical Company Details
Table 77. Otsuka Pharmaceutical Business Overview
Table 78. Otsuka Pharmaceutical Anti-tuberculosis Therapeutics Product
Table 79. Otsuka Pharmaceutical Revenue in Anti-tuberculosis Therapeutics Business (2018-2023) & (US$ Million)
Table 80. Otsuka Pharmaceutical Recent Developments
Table 81. Johnson & Johnson Company Details
Table 82. Johnson & Johnson Business Overview
Table 83. Johnson & Johnson Anti-tuberculosis Therapeutics Product
Table 84. Johnson & Johnson Revenue in Anti-tuberculosis Therapeutics Business (2018-2023) & (US$ Million)
Table 85. Johnson & Johnson Recent Developments
Table 86. Pfizer Company Details
Table 87. Pfizer Business Overview
Table 88. Pfizer Anti-tuberculosis Therapeutics Product
Table 89. Pfizer Revenue in Anti-tuberculosis Therapeutics Business (2018-2023) & (US$ Million)
Table 90. Pfizer Recent Developments
Table 91. Novartis Company Details
Table 92. Novartis Business Overview
Table 93. Novartis Anti-tuberculosis Therapeutics Product
Table 94. Novartis Revenue in Anti-tuberculosis Therapeutics Business (2018-2023) & (US$ Million)
Table 95. Novartis Recent Developments
Table 96. Abbott Company Details
Table 97. Abbott Business Overview
Table 98. Abbott Anti-tuberculosis Therapeutics Product
Table 99. Abbott Revenue in Anti-tuberculosis Therapeutics Business (2018-2023) & (US$ Million)
Table 100. Abbott Recent Developments
Table 101. AstraZeneca Company Details
Table 102. AstraZeneca Business Overview
Table 103. AstraZeneca Anti-tuberculosis Therapeutics Product
Table 104. AstraZeneca Revenue in Anti-tuberculosis Therapeutics Business (2018-2023) & (US$ Million)
Table 105. AstraZeneca Recent Developments
Table 106. Bayer Company Details
Table 107. Bayer Business Overview
Table 108. Bayer Anti-tuberculosis Therapeutics Product
Table 109. Bayer Revenue in Anti-tuberculosis Therapeutics Business (2018-2023) & (US$ Million)
Table 110. Bayer Recent Developments
Table 111. Eli Lilly Company Details
Table 112. Eli Lilly Business Overview
Table 113. Eli Lilly Anti-tuberculosis Therapeutics Product
Table 114. Eli Lilly Revenue in Anti-tuberculosis Therapeutics Business (2018-2023) & (US$ Million)
Table 115. Eli Lilly Recent Developments
Table 116. GlaxoSmithKline Company Details
Table 117. GlaxoSmithKline Business Overview
Table 118. GlaxoSmithKline Anti-tuberculosis Therapeutics Product
Table 119. GlaxoSmithKline Revenue in Anti-tuberculosis Therapeutics Business (2018-2023) & (US$ Million)
Table 120. GlaxoSmithKline Recent Developments
Table 121. Merck Company Details
Table 122. Merck Business Overview
Table 123. Merck Anti-tuberculosis Therapeutics Product
Table 124. Merck Revenue in Anti-tuberculosis Therapeutics Business (2018-2023) & (US$ Million)
Table 125. Merck Recent Developments
Table 126. Sanofi Company Details
Table 127. Sanofi Business Overview
Table 128. Sanofi Anti-tuberculosis Therapeutics Product
Table 129. Sanofi Revenue in Anti-tuberculosis Therapeutics Business (2018-2023) & (US$ Million)
Table 130. Sanofi Recent Developments
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Anti-tuberculosis Therapeutics Market Size Growth Rate by Type, 2018 VS 2022 VS 2033 (US$ Million)
Figure 2. Global Anti-tuberculosis Therapeutics Market Share by Type: 2022 VS 2033
Figure 3. Isoniazid Features
Figure 4. Rifampin Features
Figure 5. Ethambutol Features
Figure 6. Pyrazinamide Features
Figure 7. Otherr Features
Figure 8. Global Anti-tuberculosis Therapeutics Market Size Growth Rate by Application, 2018 VS 2022 VS 2033 (US$ Million)
Figure 9. Global Anti-tuberculosis Therapeutics Market Share by Application: 2022 VS 2033
Figure 10. Hospitals and Clinics Case Studies
Figure 11. Government Agencies Case Studies
Figure 12. Non-Profit Organizations Case Studies
Figure 13. Others Case Studies
Figure 14. Anti-tuberculosis Therapeutics Report Years Considered
Figure 15. Global Anti-tuberculosis Therapeutics Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 16. Global Anti-tuberculosis Therapeutics Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 17. Global Anti-tuberculosis Therapeutics Market Share by Region: 2022 VS 2033
Figure 18. Global Anti-tuberculosis Therapeutics Market Share by Players in 2022
Figure 19. Global Top Anti-tuberculosis Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-tuberculosis Therapeutics as of 2022)
Figure 20. The Top 10 and 5 Players Market Share by Anti-tuberculosis Therapeutics Revenue in 2022
Figure 21. North America Anti-tuberculosis Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. North America Anti-tuberculosis Therapeutics Market Share by Type (2018-2033)
Figure 23. North America Anti-tuberculosis Therapeutics Market Share by Application (2018-2033)
Figure 24. North America Anti-tuberculosis Therapeutics Market Share by Country (2018-2033)
Figure 25. United States Anti-tuberculosis Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. Canada Anti-tuberculosis Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. Europe Anti-tuberculosis Therapeutics Market Size YoY (2018-2033) & (US$ Million)
Figure 28. Europe Anti-tuberculosis Therapeutics Market Share by Type (2018-2033)
Figure 29. Europe Anti-tuberculosis Therapeutics Market Share by Application (2018-2033)
Figure 30. Europe Anti-tuberculosis Therapeutics Market Share by Country (2018-2033)
Figure 31. Germany Anti-tuberculosis Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. France Anti-tuberculosis Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. U.K. Anti-tuberculosis Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Italy Anti-tuberculosis Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. Russia Anti-tuberculosis Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. Nordic Countries Anti-tuberculosis Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. China Anti-tuberculosis Therapeutics Market Size YoY (2018-2033) & (US$ Million)
Figure 38. China Anti-tuberculosis Therapeutics Market Share by Type (2018-2033)
Figure 39. China Anti-tuberculosis Therapeutics Market Share by Application (2018-2033)
Figure 40. Asia Anti-tuberculosis Therapeutics Market Size YoY (2018-2033) & (US$ Million)
Figure 41. Asia Anti-tuberculosis Therapeutics Market Share by Type (2018-2033)
Figure 42. Asia Anti-tuberculosis Therapeutics Market Share by Application (2018-2033)
Figure 43. Asia Anti-tuberculosis Therapeutics Market Share by Region (2018-2033)
Figure 44. Japan Anti-tuberculosis Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. South Korea Anti-tuberculosis Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. China Taiwan Anti-tuberculosis Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 47. Southeast Asia Anti-tuberculosis Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 48. India Anti-tuberculosis Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 49. Australia Anti-tuberculosis Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 50. Middle East, Africa, and Latin America Anti-tuberculosis Therapeutics Market Size YoY (2018-2033) & (US$ Million)
Figure 51. Middle East, Africa, and Latin America Anti-tuberculosis Therapeutics Market Share by Type (2018-2033)
Figure 52. Middle East, Africa, and Latin America Anti-tuberculosis Therapeutics Market Share by Application (2018-2033)
Figure 53. Middle East, Africa, and Latin America Anti-tuberculosis Therapeutics Market Share by Country (2018-2033)
Figure 54. Brazil Anti-tuberculosis Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 55. Mexico Anti-tuberculosis Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 56. Turkey Anti-tuberculosis Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 57. Saudi Arabia Anti-tuberculosis Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 58. Israel Anti-tuberculosis Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 59. GCC Countries Anti-tuberculosis Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 60. Lupin Revenue Growth Rate in Anti-tuberculosis Therapeutics Business (2018-2023)
Figure 61. Macleods Pharmaceuticals Revenue Growth Rate in Anti-tuberculosis Therapeutics Business (2018-2023)
Figure 62. Otsuka Pharmaceutical Revenue Growth Rate in Anti-tuberculosis Therapeutics Business (2018-2023)
Figure 63. Johnson & Johnson Revenue Growth Rate in Anti-tuberculosis Therapeutics Business (2018-2023)
Figure 64. Pfizer Revenue Growth Rate in Anti-tuberculosis Therapeutics Business (2018-2023)
Figure 65. Novartis Revenue Growth Rate in Anti-tuberculosis Therapeutics Business (2018-2023)
Figure 66. Abbott Revenue Growth Rate in Anti-tuberculosis Therapeutics Business (2018-2023)
Figure 67. AstraZeneca Revenue Growth Rate in Anti-tuberculosis Therapeutics Business (2018-2023)
Figure 68. Bayer Revenue Growth Rate in Anti-tuberculosis Therapeutics Business (2018-2023)
Figure 69. Eli Lilly Revenue Growth Rate in Anti-tuberculosis Therapeutics Business (2018-2023)
Figure 70. GlaxoSmithKline Revenue Growth Rate in Anti-tuberculosis Therapeutics Business (2018-2023)
Figure 71. Merck Revenue Growth Rate in Anti-tuberculosis Therapeutics Business (2018-2023)
Figure 72. Sanofi Revenue Growth Rate in Anti-tuberculosis Therapeutics Business (2018-2023)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries